SUPN - Company ID 0001356576
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported revenue of $718.95M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $718.95M | +8.6% |
| FY 2024 | $661.82M | +8.9% |
| FY 2023 | $607.52M | -8.9% |
| FY 2022 | $667.24M | +15.1% |
| FY 2021 | $579.77M | +11.4% |
| FY 2020 | $520.40M | +32.5% |
| FY 2019 | $392.75M | -3.9% |
| FY 2018 | $408.90M | +35.3% |
| FY 2017 |
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported revenue of $718.95M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, SUPERNUS PHARMACEUTICALS, INC.'s revenue grew from $803.00K to $718.95M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $302.24M |
| +40.6% |
| FY 2016 | $215.00M | +45.8% |
| FY 2015 | $147.47M | +59.1% |
| FY 2014 | $92.68M | +671.1% |
| FY 2013 | $12.02M | +712.1% |
| FY 2012 | $1.48M | +84.3% |
| FY 2011 | $803.00K | - |